Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
Company has initiated a new R&D program to identify novel compounds that block the activity of the SARS-CoV-2 MPro protease (Nsp5), which has been designated as potential target for drug development.